Shares of Insmed (INSM +3.6%) pop after the company says the European Patent Office will grant a patent on ARIKACE, the company's clinical stage, inhaled treatment for cystic fibrosis patients with lung infections. In an exhaustive rundown, SA contributor Scott Matusow claims the drug is a superior alternative to Novartis' (NVS) TOBI for a number of reasons and also says INSM could capture a significant portion of the $424M (annually) market for CF pseudomonas lung infection treatments if top-line Phase III results (due mid-year) show promise.
Shares of Insmed (INSM +3.6%) pop after the company says the European Patent Office will grant a...
From other sites
at CNBC.com (Jun 18, 2014)
at CNBC.com (Mar 26, 2014)
at CNBC.com (Oct 27, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs